Portola Pharmaceuticals Annual Revenue, Number of Employees, Growth and Funding

Overview

Location:
Total Funding:$772M
Industry:Pharma
Founded:2003
Lead Investor(s):Morgan Stanley, Citigroup
Press

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Portola Pharmaceuticals's estimated annual revenue is currently $24M per year.
  • Portola Pharmaceuticals received $345.0M in venture funding in September 2017.
  • Portola Pharmaceuticals's estimated revenue per employee is $55,684
  • Portola Pharmaceuticals's total funding is $772M.

Employee Data

  • Portola Pharmaceuticals has 431 Employees.
  • Portola Pharmaceuticals grew their employee count by 23% last year.
  • Portola Pharmaceuticals currently has 1 job openings.

Executive Contacts

NameTitle
Mardi DierEVP & CFO
Lee MermelsteinExecutive Director, Manufacturing and Biosciences
Ernie MeyerExecutive Vice President and Chief Human Resources Officer
John CurnutteExecutive Vice President of Research & Development
Evan SusserSenior Director, QA
Alpana LoombaDirector, Clinical Operations
Charlotte FureyDirector, Clinical Data Management
Ravi Kumar MonangiDirector, IT - (Enterprise Architecture, Security, Quality/Compliance)
Vikas KawatraVice President of Information Technology
William PrettoDirector, Sales Operations

We are dedicated to discovering, developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. The company's two FDA approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.

keywords:Biotechnology,Healthcare,Pharmaceuticals

431

Number of Employees

$24M

Revenue (est)

1

Current Jobs

23%

Employee Growth %

$772M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Trifecta Clinic...
$12.3M653%N/A
Rancho BioScien...
$10.1M5423%N/A
Tlc Pharmacy
$8M435%N/A
Otsuka America
$10.7M5719%N/A
endpoint Clinic...
$55.9M29710%N/A
GCAM
$17.9M954%N/A
ZO Skin Health
$55.5M2952%N/A
Teledyne Hanson...
$8.4M4515%N/A
VIVUS
$19.3M1038%N/A
AmeriPharma
$8.4M455%N/A

Portola Pharmaceuticals News

09/03/2019 - Portola Pharmaceuticals Announces Proposed Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (PTLA) today announced plans to offer, ...

09/08/2019 - Portola Pharmaceuticals Announces Pricing of Public Offering ...

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing ...

09/03/2019 - Portola -4.8% alongside $200M share offering

Portola Pharmaceuticals (NASDAQ:PTLA) is down 4.8% after filing to offer $200M in common shares. The prospectus comes via Goldman ...

Portola Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2003-12-09$21.0MAMultipleArticle
2005-01-19$21.0MASutter Hill Ventures, Prospect VenturesArticle
2005-11-09$46.0MBAdvanced Technology VenturesArticle
2006-10-18$20.0MUndisclosedHercules Technology Growth CapArticle
2007-05-08$70.0MCMultipleArticle
2008-07-10$60.0MUndisclosedMultipleArticle
2011-11-22$89.0MUndsiclosedTemasekArticle
2014-10-06$185.4MUndisclosedMorgan StanleyArticle
2015-03-11$100.0MUndisclosedMorgan StanleyArticle
2017-09-13$345.0MUndisclosedMorgan StanleyArticle

Portola Pharmaceuticals Executive Hires

DateNameTitleReference
2006-08-30Mardi DierCFOArticle
2008-06-25Bill LisVP Biz Development/Commercial OperatioArticle
2009-09-25William LisCOOArticle
2010-03-12Charles HomcyCo-ChairmanArticle
2017-11-07John LawrenceSVP Product Development & Chief Medical OfficerArticle
2018-03-13John MoriartyEVP & General counselArticle
2018-06-26Glenn Bramesenior vice president of technical operationsArticle
2018-08-10Ernie MeyerEVP & Chief Human Resources OfficerArticle
2019-01-29Sheldon KoenigEVP & Chief Commercial OfficerArticle